Iron metabolism and iron chelation in sickle cell disease

Area of Science:

• Biochemistry
• Hematology
• Pathophysiology

Background:

• Sickle cell disease (SCD) is a prevalent hemoglobinopathy characterized by chronic inflammation.
• Iron metabolism dysregulation contributes significantly to SCD pathophysiology and organ damage.
• Understanding these mechanisms is crucial for managing SCD complications.

Purpose of the Study:

• To review recent advancements in iron metabolism relevant to sickle cell disease.
• To elucidate the role of specific proteins (hepcidin, ferroportin, HIF-1, GDF15) in SCD-related organ toxicity.
• To compare iron metabolism in SCD with other hemoglobinopathies like thalassemia.

Main Methods:

• Literature review of recent research on iron metabolism and sickle cell disease.
• Analysis of protein involvement in iron regulation and organ toxicity.
• Comparison of iron profiles (e.g., NTBI) and iron handling in SCD versus thalassemia.

Main Results:

• SCD patients exhibit distinct iron metabolism profiles, including lower non-transferrin-bound iron (NTBI) compared to thalassemia.
• Transfusion therapy in SCD can lead to iron overload, necessitating chelation.
• New oral chelators like deferasirox show promise for safety, efficacy, and patient compliance.
• Inflammatory cytokines in SCD may promote iron retention in macrophages and renal cells, influencing organ-specific toxicity.

Conclusions:

• Iron metabolism and trafficking differ significantly between SCD and other hemoglobinopathies.
• Inflammation-driven iron retention in SCD contributes to unique organ damage patterns, such as cardiomyopathy and endocrinopathies.
• Targeting iron metabolism pathways and utilizing advanced chelation therapies are key for improved SCD management.